Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $108000.0.

  • Protalix BioTherapeutics' Non Operating Income rose 17297.3% to $108000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $117000.0, marking a year-over-year increase of 11718.06%. This contributed to the annual value of $237000.0 for FY2024, which is 11251.32% up from last year.
  • Protalix BioTherapeutics' Non Operating Income amounted to $108000.0 in Q3 2025, which was up 17297.3% from -$511000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Non Operating Income high stood at $413000.0 for Q1 2025, and its period low was -$2.3 million during Q3 2021.
  • In the last 5 years, Protalix BioTherapeutics' Non Operating Income had a median value of -$442000.0 in 2022 and averaged -$534210.5.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 50736.84% in 2023, then skyrocketed by 23577.24% in 2025.
  • Protalix BioTherapeutics' Non Operating Income (Quarter) stood at -$910000.0 in 2021, then rose by 21.43% to -$715000.0 in 2022, then dropped by 13.43% to -$811000.0 in 2023, then surged by 113.19% to $107000.0 in 2024, then grew by 0.93% to $108000.0 in 2025.
  • Its last three reported values are $108000.0 in Q3 2025, -$511000.0 for Q2 2025, and $413000.0 during Q1 2025.